☆ 4.2 Meeting Abstract

RAINBOWFISH: A study of risdiplam (RG7916) in newborns with pre-symptomatic spinal muscular atrophy (SMA)

NEUROMUSCULAR DISORDERS (2019)

期刊

NEUROMUSCULAR DISORDERS

卷 29, 期 -, 页码 S187-S187

出版社

PERGAMON-ELSEVIER SCIENCE LTD

DOI: 10.1016/j.nmd.2019.06.524

关键词

-

类别

Clinical Neurology Neurosciences

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Clinical Neurology

Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)

Maryam Oskoui, John W. Day, Nicolas Deconinck, Elena S. Mazzone, Andres Nascimento, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Nathalie Goemans, Janbernd Kirschner, Anna Kostera-Pruszczyk, Laurent Servais, Gergely Papp, Ksenija Gorni, Heidemarie Kletzl, Carmen Martin, Tammy McIver, Renata S. Scalco, Hannah Staunton, Wai Yin Yeung, Paulo Fontoura, Eugenio Mercuri, SUNFISH Working Grp

Summary: Risdiplam, an oral SMN2 pre-mRNA splicing modifier, has been approved for the treatment of SMA. The SUNFISH Part 2 study demonstrated the efficacy and safety of risdiplam in type 2 and non-ambulant type 3 SMA. After 12 months of treatment, motor function improvements were maintained or further improved upon at month 24.

JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: A systematic comparison of electrophysiologic with clinical outcome measures

Tobias Kessler, Georges Sam, Wolfgang Wick, Markus Weiler

Summary: This study assessed the changes in compound muscle action potential (CMAP) amplitudes before and during risdiplam treatment in adult patients with 5q-linked spinal muscular atrophy (SMA). The results showed that the increase in CMAP amplitudes in the median nerve was associated with clinical improvement, suggesting that it could be used as an easy-to-use electrophysiological marker to monitor treatment response.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls

Basil T. Darras, Riccardo Masson, Maria Mazurkiewicz-Beldzinska, Kristy Rose, Hui Xiong, Edmar Zanoteli, Giovanni Baranello, Claudio Bruno, Dmitry Vlodavets, Yi Wang, Muna El-Khairi, Marianne Gerber, Ksenija Gorni, Omar Khwaja, Heidemarie Kletzl, Renata S. Scalco, Paulo Fontoura, Laurent Servais

Summary: In this study involving infants with type 1 SMA, treatment with risdiplam resulted in higher percentages of infants who achieved motor milestones and showed improvements in motor function compared to historical controls. Longer and larger trials are needed to confirm the long-term safety and efficacy of risdiplam in infants with type 1 SMA.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Clinical Neurology

Addressing the implementation gap in advanced therapeutics for spinal muscular atrophy in the era of newborn screening programs

Carmen Leon-Astudillo, Barry J. J. Byrne, Ramzi G. G. Salloum

Summary: Spinal muscular atrophy (SMA) is a rare genetic disease that can be improved with newborn screening and disease-modifying therapies. However, the treatment is complex and requires multidisciplinary care, posing challenges in implementation and sustainability.

FRONTIERS IN NEUROLOGY (2022)

添加到收藏夹

Review Clinical Neurology

Risdiplam: A Review in Spinal Muscular Atrophy

Julia Paik

Summary: The orally administered drug Risdiplam is the first of its kind for treating spinal muscular atrophy (SMA), improving the production of SMN protein and motor function in patients across a range of ages and subtypes of SMA.

CNS DRUGS (2022)

添加到收藏夹

Article Genetics & Heredity

Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study

Claude Cances, Dmitry Vlodavets, Giacomo Pietro Comi, Riccardo Masson, Maria Mazurkiewicz-Beldzinska, Kayoko Saito, Edmar Zanoteli, Angela Dodman, Muna El-Khairi, Ksenija Gorni, Isaac Gravestock, Janine Hoffart, Renata S. Scalco, Basil T. Darras

Summary: The ANCHOVY study findings are consistent with published natural history data on Type 1 SMA, demonstrating the devastating course of the disease, which differs significantly from risdiplam-treated infants. These results provide meaningful additions to the literature, including a broader geographical representation.

ORPHANET JOURNAL OF RARE DISEASES (2022)

添加到收藏夹

Article Clinical Neurology

Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy

Astrid Pechmann, Max Behrens, Katharina Doernbrack, Adrian Tassoni, Sabine Stein, Sibylle Vogt, Daniela Zoeller, Gunther Bernert, Tim Hagenacker, Ulrike Schara-Schmidt, Inge Schwersenz, Maggie C. Walter, Matthias Baumann, Manuela Baumgartner, Marcus Deschauer, Astrid Eisenkoelbl, Marina Flotats-Bastardas, Andreas Hahn, Veronka Horber, Ralf A. Husain, Sabine Illsinger, Jessika Johannsen, Cornelia Koehler, Heike Koelbel, Monika Mueller, Arpad von Moers, Kurt Schlachter, Gudrun Schreiber, Oliver Schwartz, Martin Smitka, Elisabeth Steiner, Eva Stoegmann, Regina Trollmann, Katharina Vill, Claudia Weiss, Gert Wiegand, Andreas Ziegler, Hanns Lochmueller, Janbernd Kirschner

Summary: This study presents real-world evidence on the effects of nusinersen treatment in patients with early-onset spinal muscular atrophy. The findings demonstrate significant improvements in motor function, particularly in children under the age of 2. However, the improvements in bulbar and respiratory function are not equivalent to those in motor function.

BRAIN (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Impairment of the neurotrophic signaling hub B-Raf contributes to motoneuron degeneration in spinal muscular atrophy

Niko Hensel, Federica Cieri, Pamela Santonicola, Ines Tapken, Tobias Schuening, Michela Taiana, Elisa Pagliari, Antonia Joseph, Silke Fischer, Natascha Heidrich, Hella Brinkmann, Sabrina Kubinski, Anke K. Bergmann, Manuela F. Richter, Klaus Jung, Stefania Corti, Elia Di Schiavi, Peter Claus

Summary: Spinal muscular atrophy (SMA) is a motor neuron disease caused by deletions of the SMN1 gene and low SMN protein levels. Recent studies have identified altered signaling networks in SMA, with two clusters structured around AKT, 14-3-3 zeta/delta, and a major hub connecting both clusters, B-Raf. Down-regulation of B-Raf and 14-3-3 zeta/delta in SMA mice and patients suggests a conserved mechanism across species, with potential therapeutic implications for motoneuron survival.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Review Pediatrics

Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: A systematic review and meta-analysis

Zhi-Juan Zhong, Pi-Mei Zheng, Hui-Hong Dou, Ji-Gan Wang

Summary: This study aimed to systematically analyze adverse events (AEs) in the treatment of spinal muscular atrophy (SMA) with Nusinersen in children and adolescents. The study found that Nusinersen-related AEs were rare and it effectively reduced common, serious, and fatal AEs in children and adolescents with SMA.

FRONTIERS IN PEDIATRICS (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Efficacy of risdiplam in spinal muscular atrophy: A systematic review and meta-analysis

Carlos Pascual-Morena, Vicente Martinez-Vizcaino, Ivan Cavero-Redondo, Irene Martinez-Garcia, Nerea Moreno-Herraiz, Celia Alvarez-Bueno, Alicia Saz-Lara

Summary: This systematic review and meta-analysis evaluated the effectiveness and safety of risdiplam in treating spinal muscular atrophy (SMA). A total of 11 studies were included, and the results indicated that risdiplam had positive effects on motor and respiratory function in patients with SMA. However, the efficacy on respiratory function was inconsistent in SMA2/3. Adverse events were reported in 16% of participants, but serious adverse events were not quantified due to limited cases. Overall, the available evidence suggests that risdiplam is an effective and safe drug for the treatment of SMA, with the stage of disease at treatment initiation potentially influencing long-term clinical benefit.

PHARMACOTHERAPY (2023)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2) : a phase 3, double-blind, randomised, placebo-controlled trial

Eugenio Mercuri, Nicolas Deconinck, Elena S. Mazzone, Andres Nascimento, Maryam Oskoui, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Odile Boespflug-Tanguy, Nathalie Goemans, Janbernd Kirschner, Anna Kostera-Pruszczyk, Laurent Servais, Marianne Gerber, Ksenija Gorni, Omar Khwaja, Heidemarie Kletzl, Renata S. Scalco, Hannah Staunton, Wai Yin Yeung, Carmen Martin, Paulo Fontoura, John W. Day

Summary: Risdiplam has shown significant improvement in motor function compared to placebo in patients with type 2 or non-ambulant type 3 spinal muscular atrophy. Motor function generally improved in younger patients and stabilized in older patients.

LANCET NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study

Claudia A. A. Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri, Janbernd Kirschner, Anna Kostera-Pruszczyk, Birgit Jaber, Ksenija Gorni, Heidemarie Kletzl, Imogen Carruthers, Carmen Martin, Francis Warren, Renata S. S. Scalco, Kathryn R. R. Wagner, Francesco Muntoni

Summary: This study investigated the safety and pharmacodynamics of risdiplam in patients with spinal muscular atrophy (SMA) who had been previously treated. The results showed that the safety and pharmacokinetics of risdiplam in previously treated patients were consistent with treatment-naive patients.

NEUROLOGY AND THERAPY (2023)

添加到收藏夹

Article Clinical Neurology

A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy

Jeffrey C. Powell, James B. Meiling, Michael S. Cartwright

Summary: This study evaluates the perceptions and experiences of adult and minor participants who previously received nusinersen and switched to risdiplam for the treatment of spinal muscular atrophy (SMA). The results suggest that most participants are satisfied when switching from nusinersen to risdiplam, with the method of delivery being a primary factor.

MUSCLE & NERVE (2023)

添加到收藏夹

Article Clinical Neurology

Longitudinal developmental profile of newborns and toddlers treated for spinal muscular atrophy

Magali Ngawa, Fabian Dal Farra, Andrei-Dan Marinescu, Laurent Servais

Summary: Spinal muscular atrophy (SMA) is caused by a mutation in the SMN1 gene. Recent drug approvals have extended the life expectancy of SMA patients. This study aimed to assess the psychomotor development of treated SMA patients. The results showed that patients treated before symptom onset had better motor scores compared to those treated after symptom onset. The study highlights the importance of considering intellectual development as an outcome in treated SMA patients. Rating: 8/10.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2023)

添加到收藏夹

Review Cell Biology

Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy

Tejal Aslesh, Toshifumi Yokota

Summary: Spinal muscular atrophy (SMA) is a common genetic neurodegenerative disorder characterized by progressive muscle weakness. The disease is caused by the loss or mutation of the SMN1 gene, with the severity inversely correlated with the number of SMN2 gene copies. Current FDA-approved treatment strategies for SMA aim to increase functional SMN production from the SMN2 gene. Additionally, gene replacement therapy using Onasemnogene abeparvovec has also been approved.

CELLS (2022)

添加到收藏夹

Article Clinical Neurology

Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment

Eugenio Mercuri, Giovanni Baranello, Odile Boespflug-Tanguy, Liesbeth De Waele, Nathalie Goemans, Janbernd Kirschner, Riccardo Masson, Elena S. Mazzone, Astrid Pechmann, Maria Carmela Pera, Carole Vuillerot, Silvia Bader-Weder, Marianne Gerber, Ksenija Gorni, Janine Hoffart, Heidemarie Kletzl, Carmen Martin, Tammy McIver, Renata S. Scalco, Wai Yin Yeung, Laurent Servais

Summary: The study demonstrated a twofold increase in SMN protein after treatment with risdiplam, suggesting its potential effectiveness in treating spinal muscular atrophy. Additionally, the safety profile of risdiplam supported the continuation of the pivotal Part 2 study.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Disease Progression in Charcot-Marie-Tooth Disease Related to MPZ Mutations: A Longitudinal Study

Vera Fridman, Stefan Sillau, Jacob Bockhorst, Kaitlin Smith, Isabella Moroni, Emanuela Pagliano, Chiara Pisciotta, Guiseppe Piscosquito, Matilde Laura, Francesco Muntoni, Chelsea Bacon, Shawna Feely, Tiffany Grider, Laurie Gutmann, Rosemary Shy, Janel Wilcox, David N. Herrmann, Jun Li, Sindhu Ramchandren, Charlotte J. Sumner, Thomas E. Lloyd, John Day, Carly E. Siskind, Sabrina W. Yum, Reza Sadjadi, Richard S. Finkel, Steven S. Scherer, Davide Pareyson, Mary M. Reilly, Michael E. Shy

Summary: This study conducted a 5-year longitudinal natural history study on 139 patients with MPZ neuropathy and found that CMTES score was sensitive to changes in patients with axonal MPZ neuropathy but not in those with demyelinating forms. Patients with moderate baseline disease severity showed the greatest changes. These findings will inform future clinical trials of MPZ neuropathies.

ANNALS OF NEUROLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Assessing Bulbar Function in Spinal Muscular Atrophy Using Patient-Reported Outcomes

Sally Dunaway Young, Amy Pasternak, Tina Duong, Katlyn E. McGrattan, Sarah Stranberg, Elizabeth Maczek, Courtney Dias, Whitney Tang, Dana Parker, Alexis Levine, Alyssa Rohan, Connie Wolford, William Martens, Michael P. McDermott, Basil T. Darras, John W. Day

Summary: This study aimed to assess bulbar function using patient-reported outcome measures (PROs) and determine their relationships with clinical characteristics. Results showed that patients with spinal muscular atrophy (SMA) experience problems with voice and swallowing. Further refinement and assessment of functional bulbar scales are needed to determine their relevance and responsiveness to changes in SMA.

JOURNAL OF NEUROMUSCULAR DISEASES (2023)

添加到收藏夹

Article Clinical Neurology

Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants

Christopher J. Record, Mariola Skorupinska, Matilde Laura, Alexander M. Rossor, Davide Pareyson, Chiara Pisciotta, Shawna M. E. Feely, Thomas E. Lloyd, Rita Horvath, Reza Sadjadi, David N. Herrmann, Jun Li, David Walk, Sabrina W. Yum, Richard A. Lewis, John Day, Joshua Burns, Richard S. Finkel, Mario A. Saporta, Sindhu Ramchandren, Michael D. Weiss, Gyula Acsadi, Vera Fridman, Francesco Muntoni, Roy Poh, James M. Polke, Stephan Zuchner, Michael E. Shy, Steven S. Scherer, Mary M. Reilly

Summary: This study collected demographic, clinical and genetic data on CMT patients with GJB1 variants and found that males are more severely affected than females. It also found that some reported GJB1 variants remain classified as variants of uncertain significance. By analyzing a large cohort, the study showed that enhanced variant interpretation increases the proportion of pathogenic variants in GJB1.

BRAIN (2023)

添加到收藏夹

Article Cell & Tissue Engineering

Generation of two induced pluripotent stem cell lines from spinal muscular atrophy type 1 patients carrying no functional copies of SMN1 gene

Wenshu Zenga, Xiaohui Kong, Christina Alamanaa, Yu Liu, Jessica Guzman, Paul D. Pang, John W. Day, Joseph C. Wu

Summary: Spinal muscular atrophy (SMA) is a severe neurodegenerative muscular disease caused by the loss of survival of motor neuron 1 (SMN1) genes. Two iPSC lines were generated from SMA type I patients with SMN1 mutations, and their pluripotency and ability to differentiate into three germ layers were validated. These iPSC lines can be used to generate skeletal muscles to model the muscle atrophy of SMA, providing a complementary platform for in vitro drug screening.

STEM CELL RESEARCH (2023)

添加到收藏夹

Article Clinical Neurology

Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)

Richard S. Finkel, Basil T. Darras, Jerry R. Mendell, John W. Day, Nancy L. Kuntz, Anne M. Connolly, Craig M. Zaidman, Thomas O. Crawford, Russell J. Butterfield, Perry B. Shieh, Gihan Tennekoon, John F. Brandsema, Susan T. Iannaccone, John Shoffner, Sarah Kavanagh, Thomas A. Macek, Sitra Tauscher-Wisniewski

Summary: This study assessed the safety and efficacy of intrathecal onasemnogene abeparvovec in SMA patients. The results showed that intrathecal administration was safe and effective at an appropriate dose. Older patients showed significant improvement in HFMSE score after treatment.

JOURNAL OF NEUROMUSCULAR DISEASES (2023)

添加到收藏夹

Article Orthopedics

ADAPTations to low load blood flow restriction exercise versus conventional heavier load resistance exercise in UK military personnel with persistent knee pain: protocol for the ADAPT study, a multi-centre randomized controlled trial

Robyn P. Cassidy, Kieran M. Lunt, Russell J. Coppack, Alexander N. Bennett, James L. J. Bilzon, M. Polly Mcguigan, Natalie Egginton, Edward Sellon, Jo Day, Peter Ladlow

Summary: This study aims to compare the efficacy of high frequency low load blood flow restriction training (LL-BFR) to conventional heavier load resistance training (HL-RT) on measures of physical function and pain in adults with persistent knee pain. The study found that LL-BFR can improve muscle strength, hypertrophy, and pain without the need for high mechanical loads, making it a potential treatment option for patients with functional deficits who cannot tolerate heavy load resistance training.

BMC MUSCULOSKELETAL DISORDERS (2023)

添加到收藏夹

Meeting Abstract Clinical Neurology

Assessment of maximal effort for weaker individuals with NMD during the assisted six-minute cycling test

Y. Blumberg, C. De Monts, W. Tang, S. Montalvo, P. Ataide, S. Dunaway Young, M. Wheeler, E. Ashley, J. Myers, J. Day, J. Christle, T. Duong

NEUROMUSCULAR DISORDERS (2023)

添加到收藏夹

Meeting Abstract Clinical Neurology

Assisted Six Minute Cycle Test (A6MCT): A Feasible and Valid Measurement of Functional and Fatigue Changes in Individuals with Spinal Muscular Atrophy

W. Tang, S. Montalvo, C. De Monts, S. Dunaway Young, P. Ataide, N. Ni Ghiollagain, V. Stevens, D. Parker, Z. He, C. Tesi Rocha, J. Day, T. Duong

NEUROMUSCULAR DISORDERS (2023)

添加到收藏夹

Meeting Abstract Clinical Neurology

Effect of apitegromab on motor function at 36 months in patients with nonambulatory spinal muscular atrophy aged 2-12 years old

T. Crawford, B. Darras, J. Day, D. De Vivo, E. Mercuri, A. Nascimento, E. Mazzone, A. Waugh, G. Song, R. Evans, J. Marantz

NEUROMUSCULAR DISORDERS (2023)

添加到收藏夹

Meeting Abstract Economics

COMPARATIVE REAL-WORLD RETROSPECTIVE DATA ANALYSIS OF COMORBID CONDITIONS AND HEALTHCARE UTILIZATION FOR PATIENTS WITH MYOTONIC DYSTROPHY OVER A 5-YEAR TIMEFRAME

J. W. Day, C. Y. Chen, K. Munoz, R. A. Brook, N. L. Kleinman, B. McEvoy, H. Cho, M. Stahl, L. J. Tai

VALUE IN HEALTH (2023)

添加到收藏夹

Article Clinical Neurology

Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial

Charles A. Thornton, Richard Thomas Moxley, Katy Eichinger, Chad Heatwole, Laurence Mignon, W. David Arnold, Tetsuo Ashizawa, John W. Day, Gersham Dent, Matthew K. Tanner, Tina Duong, Ericka P. Greene, Laura Herbelin, Nicholas E. Johnson, Wendy King, John Kissel, Doris G. Leung, Donovan J. Lott, Daniel A. Norris, Evan M. Pucillo, Wendy Schell, Jeffrey M. Statland, Nikia Stinson, Sub H. Subramony, Shuting Xia, Kathie M. Bishop, C. Frank Bennett

Summary: This study assessed the safety of baliforsen, an antisense oligonucleotide, in patients with myotonic dystrophy type 1. The results showed that baliforsen was generally well tolerated, but the drug concentrations in skeletal muscle did not reach predicted therapeutic levels. These findings support further investigation of ASOs as a treatment approach for myotonic dystrophy type 1, with a focus on improving drug delivery to muscle.

LANCET NEUROLOGY (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy

John W. Day, Jerry R. Mendell, Arthur H. M. Burghes, Rudolf W. van Olden, Rishi R. Adhikary, Keith W. Dilly

Summary: A study on pediatric patients with spinal muscular atrophy (SMA) in the United States found that a certain percentage of patients had elevated titers of anti-AAV9 binding antibodies. The prevalence of elevated titers decreased as age increased, suggesting transplacental maternal transfer of antibodies. No patterns of geographic variations in antibody prevalence were confirmed. Lower magnitudes of elevated titers declined more rapidly than greater magnitudes. Retesting should be considered when patients have elevated titers, and elevated titers at a young age do not affect subsequent treatment.

MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT (2023)

添加到收藏夹

Meeting Abstract Biotechnology & Applied Microbiology

A Human PBMC Assay of Type 1 Interferon Responses to Closely Related AAV Vectors

Bradley A. Hamilton, Rachana Patil, Soohyun Kim, John W. Day, J. Fraser Wright

MOLECULAR THERAPY (2023)

添加到收藏夹

Meeting Abstract Clinical Neurology

SUNFISH Parts 1 and 2: 4-year efficacy and safety data of risdiplam in Types 2 and 3 spinal muscular atrophy (SMA)

A. Kostera-Pruszczyk, J. Day, N. Deconinck, E. Mazzone, A. Nascimento, M. Oskoui, K. Saito, C. Vuillerot, G. Baranello, O. Boespflug-Tanguy, N. Goemans, J. Kirschner, L. Servais, J. Braid, M. Gerber, K. Gorni, C. Martin, W. Yeung, R. Scalco, E. Mercuri

EUROPEAN JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.